Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial-Reference-Cited by-同舟云学术

Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial

Published:2020-05-07 Issue:1 Volume:35 Page:143-155
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Wulf Gerald G., ,Altmann Bettina,Ziepert Marita,D’Amore Francesco,Held Gerhard,Greil Richard,Tournilhac Olivier,Relander Thomas,Viardot Andreas,Wilhelm Martin,Wilhelm Christian,Pezzutto Antonio^ORCID,Zijlstra Josee M.,Neste Eric Van Den,Lugtenburg Pieternella J.,Doorduijn Jeanette K.,Gelder Michel van,van Imhoff Gustaaf W.,Zettl Florian,Braulke Friederike,Nickelsen Maike,Glass Bertram,Rosenwald Andreas,Gaulard Philippe,Loeffler Markus,Pfreundschuh Michael^ORCID,Schmitz Norbert,Trümper Lorenz

Funder

Bundesministerium für Bildung und Forschung

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/s41375-020-0838-5.pdf

Reference56 articles.

1. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–90.

2. Wang SS, Vose J. Epidemiology and prognosis of T-Cell lymphoma. In: Foss F editor. T-Cell lymphomas. Springer; New York 2013.

3. Schmitz N, Trumper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2010;116:3418–25.